IBM Watson for Clinical Trial Matching (2016–2022)
IBM marketed Watson as a system that could read cancer patients' records and match them to open trials. A small number of cancer centers tried it. Adoption stayed narrow, and the reasoning behind its recommendations was hard to audit.
Few sites kept using it, and IBM's health unit struggled commercially.
IBM sold Watson Health to the private equity firm Francisco Partners in 2022. Buyers of clinical AI grew skeptical of recommendations they could not inspect.
Oracle's agents are deliberately narrow and rule-based, and Oracle states they do not calculate clinical measurements. That reads as a direct answer to Watson's auditability problem.
